子宮頸がん診断の市場レポート：検査タイプ、年齢層、地域別、2024～2032年

世界の子宮頸がん診断の市場規模は2023年に80億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに123億米ドルに達し、2024～2032年の間に4.8％の成長率（CAGR）を示すと予測しています。

子宮頸がん診断は、ヒトパピローマウイルス（HPV）の異常細胞や株を評価するための一連の高度な臨床検査、ツール、手順に依存しています。これらの検査は、円錐切除、パンチ生検、子宮頸部内掻爬、コルポスコピー中の子宮頸部の精密検査のための電線ループによって得られた組織のサンプルを採取することによって行われます。発見後は、血液検査、胸部X線検査、CT検査、MRI検査、PET検査、膀胱や直腸の視触診などを行い、病期を判定します。

梅毒、クラミジア、淋病、後天性免疫不全症候群（HIV/AIDS）などの性行為感染症（STI）と診断される患者数が大幅に増加しているため、世界的にHPV感染のリスクが高まっています。これは、子宮頸がんを発症する可能性を高める喫煙者の増加とともに、市場の成長を後押しする主要要因の1つとなっています。さらに、早期診断に対する意識の高まりが、迅速かつ正確な検査結果を提供するHPV家庭用検査キットの採用を後押ししています。有利な償還政策の存在も市場の成長を支えています。これとは別に、個別化された治療計画に対する嗜好の高まりが、子宮頸がん診断の需要を高めています。さらに、手術、放射線療法、化学療法、コーン生検、免疫療法、気管切除術など、さまざまな治療オプションが利用可能なことも、市場成長に寄与しています。さらに、低コストで効率的な検査製品の開発が重視されるようになっていることも、市場の成長を後押しすると予想されます。

本レポートで扱う主要質問

• 子宮頸がん診断の市場の世界市場規模は？
• 2024～2032年における子宮頸がん診断の市場の世界市場成長率は？
• 世界の子宮頸がん診断の市場を牽引する主要因は何か？
• 世界の子宮頸がん診断の市場に対するCOVID-19の影響は？
• 世界の子宮頸がん診断の市場の検査タイプ別内訳は？
• 子宮頸がん診断の市場の世界における主要地域は？
• 世界の子宮頸がん診断の市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の子宮頸がん診断市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：検査タイプ別

• パップ検査
• HPV検査
• 子宮頸部生検
• 膣鏡検査
• その他

第7章 市場内訳：年齢層別

• 20～35歳
• 35歳以上

第8章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第9章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第12章 価格分析

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • Arbor Vita Corporation
  • Becton, Dickinson and Company
  • Cooper Surgical Inc.
  • F. Hoffmann-La Roche AG
  • Guided Therapeutics Inc.
  • Hologic Inc.
  • Qiagen
  • Quest Diagnostics Incorporated
  • Siemens Healthcare GmbH

List of Figures

• Figure 1: Global: Cervical Cancer Diagnostics Market: Major Drivers and Challenges
• Figure 2: Global: Cervical Cancer Diagnostics Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Cervical Cancer Diagnostics Market: Breakup by Test Type (in %), 2023
• Figure 5: Global: Cervical Cancer Diagnostics Market: Breakup by Age Group (in %), 2023
• Figure 6: Global: Cervical Cancer Diagnostics Market: Breakup by Region (in %), 2023
• Figure 7: Global: Cervical Cancer Diagnostics (Pap Testing) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Cervical Cancer Diagnostics (Pap Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Cervical Cancer Diagnostics (HPV Testing) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Cervical Cancer Diagnostics (HPV Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Cervical Cancer Diagnostics (Cervical Biopsies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Cervical Cancer Diagnostics (Cervical Biopsies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Cervical Cancer Diagnostics (Colposcopy) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Cervical Cancer Diagnostics (Colposcopy) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Cervical Cancer Diagnostics (Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Cervical Cancer Diagnostics (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Cervical Cancer Diagnostics (20 to 35 years) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Cervical Cancer Diagnostics (20 to 35 years) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Cervical Cancer Diagnostics (Above 35 years) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Cervical Cancer Diagnostics (Above 35 years) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: North America: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: North America: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: United States: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: United States: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: Canada: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: Canada: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Asia-Pacific: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Asia-Pacific: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: China: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: China: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Japan: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Japan: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: India: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: India: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: South Korea: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: South Korea: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: Australia: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: Australia: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: Indonesia: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: Indonesia: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: Others: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: Others: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: Europe: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: Europe: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: Germany: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: Germany: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: France: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: France: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: United Kingdom: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: United Kingdom: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: Italy: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: Italy: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: Spain: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: Spain: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: Russia: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: Russia: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: Others: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: Others: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Latin America: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Latin America: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Brazil: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Brazil: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Mexico: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Mexico: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 65: Others: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 66: Others: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 67: Middle East and Africa: Cervical Cancer Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
• Figure 68: Middle East and Africa: Cervical Cancer Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 69: Middle East and Africa: Cervical Cancer Diagnostics Market: Breakup by Country (in %), 2023
• Figure 70: Global: Cervical Cancer Diagnostics Industry: SWOT Analysis
• Figure 71: Global: Cervical Cancer Diagnostics Industry: Value Chain Analysis
• Figure 72: Global: Cervical Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Cervical Cancer Diagnostics Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Cervical Cancer Diagnostics Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
• Table 3: Global: Cervical Cancer Diagnostics Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
• Table 4: Global: Cervical Cancer Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Cervical Cancer Diagnostics Market: Competitive Structure
• Table 6: Global: Cervical Cancer Diagnostics Market: Key Players

The global cervical cancer diagnostics market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.

Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.

A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cervical cancer diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and age group.

Breakup by Test Type:

Pap Testing

HPV Testing

Cervical Biopsies

Colposcopy

Others

Breakup by Age Group:

20 to 35 years

Above 35 years

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.

Key Questions Answered in This Report

• 1. How big is the global cervical cancer diagnostics market?
• 2. What is the expected growth rate of the global cervical cancer diagnostics market during 2024-2032?
• 3. What are the key factors driving the global cervical cancer diagnostics market?
• 4. What has been the impact of COVID-19 on the global cervical cancer diagnostics market?
• 5. What is the breakup of the global cervical cancer diagnostics market based on the test type?
• 6. What are the key regions in the global cervical cancer diagnostics market?
• 7. Who are the key players/companies in the global cervical cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cervical Cancer Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Test Type

• 6.1 Pap Testing
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 HPV Testing
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Cervical Biopsies
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Colposcopy
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Age Group

• 7.1 20 to 35 years
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Above 35 years
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Arbor Vita Corporation
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Becton, Dickinson and Company
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Cooper Surgical Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 F. Hoffmann-La Roche AG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Guided Therapeutics Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 SWOT Analysis
  • 13.3.7 Hologic Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Qiagen
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Quest Diagnostics Incorporated
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Siemens Healthcare GmbH
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 SWOT Analysis